Home » Newsletters » BioWorld Science

BioWorld Science

March 8, 2011

View Archived Issues

Four-marker signature exhibits improved prognostic accuracy in prostate cancer progression

Azacitidine has dual mechanism of action in resistant cancer cells

PTC Therapeutics achieves first milestone in BMI-1 collaboration with Wellcome Trust

BioDelivery Sciences announces results of FDA meeting on BEMA-delivered buprenorphine/naloxone

Novel HCV NS3/NS4A inhibitors patented by Idenix

Novel IAP inhibitors for treatment of cancer designed at Takeda

Servier presents new anticancer dihydroindolone analogues

Infinity Pharma's IPI-926 enters phase II trial and receives FDA orphan status in chondrosarcoma

Noscira presents new inhibitors of beta-secretase 1 and Abeta production

Kissei claims new catechol O-methyltransferase inhibitors

French scientists present new CK II inhibitors

FDA clears Palatin Technologies' IND for phase IIa PL-3994 trial in asthma

Cempra Pharma provides pipeline update on solithromycin and Taksta

InterMune receives approval for Esbriet in Europe

Endo Pharma launches Fortesta testosterone gel in U.S.

Novel TGFR-2-based trap T22d35 reduces tumor growth in vivo

ACT Biotech files SPA with FDA for phase III telatinib trial

Lycera and Merck & Co. enter into autoimmune treatment collaboration

AGS-004 delays rebound of HIV during interruption of antiretroviral therapy

Phase III ORAL Sync trial of Pfizer's tofacitinib meets primary endpoints

FDA approves removal of boxed warning regarding liver injury from Letairis label

European Commission approves Firazyr self-administration label for HAE

Ziopharm grants exclusive license to Solasia for Zinapar in Asia

Vical and EMA reach agreement on endpoints for pivotal phase III trial of TransVax vaccine

MediciNova and Zhejiang Medicine form partnership for MN-221 in China

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...